INNOCARE(09969) has reached an agreement with the FDA to initiate phase III study on the use of Ocrelizumab in treating primary progressive multiple sclerosis (PPMS) patients.

INNOCARE (09969) announced that the company has successfully held a post-Phase II clinical meeting with the Food and Drug Administration (FDA) in the United States for the clinical development of ocrelizumab in the treatment of multiple sclerosis (MS). The FDA and the company have reached an agreement to initiate a Phase III study for ocrelizumab in the treatment of primary progressive multiple sclerosis (PPMS) patients. This is an important milestone for the company's ongoing efforts to develop innovative and effective therapies to meet the unmet medical needs of MS patients. The US FDA has also recommended the company to initiate a second Phase III clinical trial for ocrelizumab in the treatment of progressive forms of multiple sclerosis (PMS) in secondary progressive multiple sclerosis (SPMS) patients. The company will spare no effort to accelerate the progress of these projects and provide these much-needed therapies for patients. Through collaborative efforts, the company is one step closer to improving the quality of life for MS patients.